Recombinant MAGE-A3 protein immunotherapy (GlaxoSmithKline)

N/A

Report date: 2024/01/10 15:11:28

Base Information

Drug NameRecombinant MAGE-A3 protein immunotherapy (GlaxoSmithKline)
Drug Alias Name重组MAGE-A3蛋白免疫疗法-葛兰素史克recMAGE-A3
ClassificationBiologics > Protein drugs > Recombinant protein
Mechanisms of ActionMelanoma-associated antigen 3 modulators
TargetsMelanoma-associated antigen 3
Therapy Area/IndicationsUrinary Bladder Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaUkrainePoland +[10] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline Plc
Active IndicationsN/A
Inactive IndicationsUrinary Bladder Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A